Hormone replacement therapy market accounted for US$ 7.16 billion in 2020 and is estimated to be US$ 14.7 billion by 2030 and is anticipated to register a CAGR of 7.50%. Hormone replacement therapy (HRT), also known as menopausal hormone therapy or postmenopausal hormone therapy, is a form of hormone therapy used to treat symptoms associated with female menopause.These symptoms can include hot flashes, vaginal atrophy, accelerated skin aging, vaginal dryness, decreased muscle mass, sexual dysfunction, and bone loss. They are in large part related to the diminished levels of sex hormones that occur during menopause. The main hormonal medications used in HRT for menopausal symptoms are estrogens and progestogens, among which progesterone is the major naturally-occurring female sex hormone and also a manufactured medication used in menopausal hormone therapy. Though both can have symptomatic benefits, progestogen is specifically added to estrogen regimens when the uterus is still present. Unopposed estrogen therapy promotes endometrial thickening and can increase the risk of cancer, while progestogen reduces this risk. Androgens like testosterone are sometimes used as well. HRT is available through a variety of different routes.
The report " Global Hormone Replacement Therapy Market, By Therapy Type (Human Growth Hormone (HGH) Replacement Therapy, Testosterone Replacement Therapy, Thyroid Replacement Therapy, Estrogen Replacement Therapy), By Application (Growth Hormone Deficiency, Menopause, Hypothyroidism, Male Hypogonadism, and Others), By Route of Administration (Oral, Parenteral, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa ) - Trends, Analysis and Forecast till 2030”
Key Highlights:
· In December 2020, US FDA approved the Myovant Sciences' Orgovyx (relugolix), which is an orally administered treatment that works by blocking the pituitary from making hormones called LH and FSH, thus resulting in the reduction within the amount of testosterone produced by the testicles. Thus, aiding within the treatment of adult patients with advanced prostatic adenocarcinoma.
· In August 2020, Bayer AG announced the acquisition of KanDy Therapeutics, Inc, which aids within the expansion of Bayer's women's drug pipeline by adding KanDy's menopause drug thereto portfolio.
Analyst View:
High prevalence of hormone related disorder is expected to drastically increase the demand for hormone replacement therapy market in near future. As per estimated of American Thyroid Association (ATA), More than 12 percent of the U.S. population will develop a thyroid condition during their lifetime and around 20 million Americans have some form of thyroid disease.
Before purchasing this report, request a sample or make an inquiry by clicking the following link:
https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/141
Key Market Insights from the report:
The global hormone replacement therapy market accounted for US$ 7.16 billion in 2020 and is estimated to be US$ 14.7 billion by 2030 and is anticipated to register a CAGR of 7.50%. The global hormone replacement therapy market has been segmented on the basis of therapy type, application, route of administration, distribution channel and region.
· By Therapy Type, the market is segmented into human growth hormone (HGH) replacement therapy, testosterone replacement therapy, thyroid replacement therapy, and estrogen replacement therapy.
· By Application, the market is segmented into growth hormone deficiency, menopause, hypothyroidism, male hypogonadism, and others.
· By Route of Administration, the Global Hormone Replacement Therapy Market is segmented into oral, parenteral, and others.
· By Distribution Channel, the Global Hormone Replacement Therapy Market is segmented into hospital, retail pharmacies, and online pharmacies.
· By Region, the Global Hormone Replacement Therapy Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America region is expected to be the largest hormone replacement therapy market.
Competitive Landscape:
The Key players operating in the global Hormone replacement therapy market includes, Merck KgaA, Abbott Laboratories, Eli Lilly and Company, Novartis International AG, Pfizer Inc., Bayer AG, QuatRx Pharmaceuticals, Mylan N.V., Teva Pharmaceutical Industries Ltd., Amgen, Inc., and Novo Nordisk A/S.
The market provides detailed information regarding the industrial base, productivity, strengths, manufacturers, and recent trends which will help companies enlarge the businesses and promote financial growth. Furthermore, the report exhibits dynamic factors including segments, sub-segments, regional marketplaces, competition, dominant key players, and market forecasts. In addition, the market includes recent collaborations, mergers, acquisitions, and partnerships along with regulatory frameworks across different regions impacting the market trajectory. Recent technological advances and innovations influencing the global market are included in the report.
